J2N-MC-JZNX

1) Have confirmed diagnosis of CLL/SLL as defined by these iwCLL 2018 criteria.

2) Have received prior CLL/SLL treatment

3) Have received at least 1, but not more than 3 lines of prior treatment for CLL/SLL.

4) Have received a covalent BTK inhibitor.

5) Have a requirement for therapy consistent with iwCLL 2018 criteria for initiation of therapy.

6) Capable of swallowing oral study medication.

7) Have an Eastern Cooperative Oncology Group Performance Status (ECOG) score of 0 to 2.

1) Have received prior treatment with a BTK degrader and a noncovalent BTK inhibitor.

2) Have a history of greater than or equal to (>=) Grade 3 bleeding due to treatment with a BTK inhibitor.

3) Have known or suspected Richter’s transformation.

4) Have known or suspected history of central nervous system involvement by CLL/SLL.

5) Previous or concurrent cancer distinct from CLL/SLL within 3 years before randomization. Exceptions may occur with documented sponsor approval. Examples include:
|— a) Non-melanoma skin cancer or lentigo maligna melanoma;
|— b) Cervical carcinoma in situ;
|— c) Localized prostate cancer undergoing active surveillance, and;
|— d) Localized (for example, lymph node negative) breast cancer with no evidence of active disease present for more than 3 years. Individual may be receiving adjuvant hormonal therapy.

View more trial information